ABOUT
SebOMIX is a University of Manchester spinout company developing rapid, non-invasive diagnostic technology for Parkinson’s disease using simple skin swabs.
Founded on pioneering research in mass spectrometry and biomarker discovery, SebOMIX is advancing a new approach to disease detection by analysing sebum, the naturally occurring oily substance produced by the skin.
The company’s technology has the potential to identify molecular signatures associated with Parkinson’s disease in just minutes, helping clinicians diagnose the condition earlier and more accurately.